Galderma Laboratories has completed two independent Phase 3 clinical trials of CD07805/47, a topical gel under investigation in adults with moderate to severe facial erythema (redness) of rosacea.

Rosacea is a chronic, inflammatory and vascular condition of the face and eyes characterised by persistent erythema, flushing, inflammatory lesions and visible blood vessels.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The two randomised vehicle-controlled multicentre Phase 3 trials demonstrated the efficacy and safety of CD07805/47 applied topically once daily versus vehicle (control) in adult patients with moderate to severe facial erythema of rosacea.

University of Louisville dermatology clinical professor Joseph Fowler said the facial erythema associated with rosacea can have a negative psychosocial impact on patients, giving rise to anxiety and creating low self-confidence and embarrassment.

Galderma Laboratories president Francois Fournier said the company is committed to partnering with healthcare providers to drive innovation and develop treatments for patients with dermatologic conditions.

"These results are encouraging because this investigational treatment has the potential to one day address unmet needs in this highly prevalent condition," Fournier added.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company plans to submit a New Drug Application for CD07805/47 to the US Food & Drug Administration and to the European Medicines Agency.

Galderma is a global pharmaceutical company that develops a range of therapies for dermatological conditions, including acne, rosacea, onychomycosis, psoriasis and steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence.

In 2011, Galderma acquired a Swedish medical device company, Q-Med, strengthening Galderma’s presence in the aesthetic and corrective market.